{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T09:38:45Z","timestamp":1770457125679,"version":"3.49.0"},"reference-count":52,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Treatment"],"published-print":{"date-parts":[[2022,2,17]]},"DOI":"10.1080\/09546634.2020.1773385","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T09:26:46Z","timestamp":1591694806000},"page":"606-612","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Off-label studies on ruxolitinib in dermatology: a review"],"prefix":"10.1080","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7444-8882","authenticated-orcid":false,"given":"Jessica","family":"Wu","sequence":"first","affiliation":[{"name":"David Geffen School of Medicine, University of California Los Angeles","place":["Los Angeles, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Smogorzewski","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Harbor-UCLA Medical Center","place":["Torrance, USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,6,9]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.12.005"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110557"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110556"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.235"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.09.035"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.104"},{"issue":"5","key":"e_1_3_2_8_1","first-page":"508","article-title":"Aggressive skin cancers occurring in patients treated with the janus kinase inhibitor ruxolitinib","volume":"16","author":"Blechman AB","year":"2017","unstructured":"Blechman AB, Cabell CE, Weinberger CH, et\u00a0al. Aggressive skin cancers occurring in patients treated with the janus kinase inhibitor ruxolitinib. J Drugs Dermatol. 2017;16(5):508\u2013511.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.296"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000494613"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.01.032"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.08.040"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/1203475417716363"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.2927"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.4445"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.13598"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.14192"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23871"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15383"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.03.024"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1159\/000479722"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.10.016"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3645"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.08.042"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3006"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-018-0519-6"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.02.015"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2019.02.006"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy255"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1412997"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy105"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.10.044"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-017-1304-5"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.12.018"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13994"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.03.016"},{"issue":"2","key":"e_1_3_2_37_1","first-page":"504","article-title":"Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor","volume":"179","author":"Nasifoglu S","year":"2018","unstructured":"Nasifoglu S, Heinrich B, Welzel J. Successful therapy for pyoderma gangrenosum with a Janus kinase 2 inhibitor. Br J Dermatol. 2018;179(2):504\u2013505.","journal-title":"Br J Dermatol"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.0756"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.02.049"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.02.023"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.09.073"},{"key":"e_1_3_2_42_1","volume-title":"TRuE AD2 \u2013 An Efficacy and Safety Study of Ruxolitinb Cream in Adolescents and Adults with Atopic Dermatitis: NCT03745651","author":"ClinicalTrials.gov","year":"2020","unstructured":"ClinicalTrials.gov. TRuE AD2 \u2013 An Efficacy and Safety Study of Ruxolitinb Cream in Adolescents and Adults with Atopic Dermatitis: NCT03745651. Bethesda (MD): National Library of Medicine; 2020."},{"key":"e_1_3_2_43_1","volume-title":"TRuE AD1 \u2013 An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis: NCT03745638","author":"ClinicalTrials.gov","year":"2020","unstructured":"ClinicalTrials.gov. TRuE AD1 \u2013 An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis: NCT03745638. Bethesda (MD): National Library of Medicine; 2020."},{"key":"e_1_3_2_44_1","volume-title":"A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants with Atopic Dermatitis. NCT03920852","author":"ClinicalTrials.gov","year":"2020","unstructured":"ClinicalTrials.gov. A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants with Atopic Dermatitis. NCT03920852. Bethesda (MD): National Library of Medicine; 2020."},{"key":"e_1_3_2_45_1","volume-title":"A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects with Atopic Dermatitis. NCT03257644","author":"ClinicalTrials.gov.","year":"2020","unstructured":"ClinicalTrials.gov. A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects with Atopic Dermatitis. NCT03257644. Bethesda (MD): National Library of Medicine; 2020."},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2012.10.018"},{"key":"e_1_3_2_47_1","volume-title":"A Dose Ranging Study of the Effect of Ruxoltinib Phosphate Cream When Applied to Patients with Plaque Psoriasis. NCT00778700","author":"ClinicalTrials.gov.","year":"2020","unstructured":"ClinicalTrials.gov. A Dose Ranging Study of the Effect of Ruxoltinib Phosphate Cream When Applied to Patients with Plaque Psoriasis. NCT00778700. Bethesda (MD): National Library of Medicine; 2020."},{"key":"e_1_3_2_48_1","volume-title":"A Study of INCB018424 Phosphate Cream in Subjects with Vitiligo. NCT03099304","author":"ClinicalTrials.gov.","year":"2020","unstructured":"ClinicalTrials.gov. A Study of INCB018424 Phosphate Cream in Subjects with Vitiligo. NCT03099304. Bethesda (MD): National Library of Medicine; 2020."},{"key":"e_1_3_2_49_1","volume-title":"INCB018424 in the Treatment of Cutaneous Lichen Planus. NCT03697460","author":"ClinicalTrials.gov.","year":"2020","unstructured":"ClinicalTrials.gov. INCB018424 in the Treatment of Cutaneous Lichen Planus. NCT03697460. Bethesda (MD): National Library of Medicine; 2020."},{"key":"e_1_3_2_50_1","volume-title":"Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients with Psoriasis. NCT00617994","author":"ClinicalTrials.gov","year":"2020","unstructured":"ClinicalTrials.gov. Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients with Psoriasis. NCT00617994. Bethesda (MD): National Library of Medicine; 2020."},{"key":"e_1_3_2_51_1","volume-title":"Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2). NCT04057573","author":"ClinicalTrials.gov.","year":"2020","unstructured":"ClinicalTrials.gov. Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2). NCT04057573. Bethesda (MD): National Library of Medicine; 2020."},{"key":"e_1_3_2_52_1","volume-title":"Topical Ruxolitinib Evaluation in Vitiligo Study 1 TRuE-V1). NCT04052425","author":"ClinicalTrials.gov.","year":"2020","unstructured":"ClinicalTrials.gov. Topical Ruxolitinib Evaluation in Vitiligo Study 1 TRuE-V1). NCT04052425. Bethesda (MD): National Library of Medicine; 2020."},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-6-79"}],"container-title":["Journal of Dermatological Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/09546634.2020.1773385","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T12:30:12Z","timestamp":1770121812000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/09546634.2020.1773385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,9]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2,17]]}},"alternative-id":["10.1080\/09546634.2020.1773385"],"URL":"https:\/\/doi.org\/10.1080\/09546634.2020.1773385","relation":{},"ISSN":["0954-6634","1471-1753"],"issn-type":[{"value":"0954-6634","type":"print"},{"value":"1471-1753","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijdt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijdt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-04-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}